Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
PROTHENA CORP PUBLIC LTD CO 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial details
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $18.6M versus $125.8M loss; six-month net income $14.1M driven by $50.0M Novo Nordisk milestone
- Cash, equivalents and restricted cash $289.1M with no debt; year-end guidance reduced to approximately $259M midpoint
- Share repurchases totaled 2.24M shares and $22.3M in H1 under the $100.0M authorization
- Partnered pipeline advances toward major catalysts: prasinezumab Phase 3 completion expected 2029 and moponetug Phase 2 completion in 1H 2027
- Potential $55M PRX019 milestone excluded from 2026 guidance; BMS advancement decision expected by year-end 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PROTHENA CORP PUBLIC LTD CO 8-K filings
Get the next PRTA 8-K as it lands
Follow PRTA for push alerts, or ask the research agent what this filing means.